US 12,065,435 B2
Compounds for the treatment of glycogen storage disorders
Or Kakhlon, Jerusalem (IL); Miguel Enrique Weil, Tel-Aviv (IL); and Leonardo Javier Solmesky, Yavne (IL)
Assigned to HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., Jerusalem (IL); and RAMOT AT TEL-AVIV UNIVERSITY LTD., Tel Aviv (IL)
Filed by HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., Jerusalem (IL); and RAMOT AT TEL-AVIV UNIVERSITY LTD., Tel Aviv (IL)
Filed on Oct. 27, 2022, as Appl. No. 17/975,214.
Application 17/334,905 is a division of application No. 16/485,577, granted, now 11,053,231, issued on Jul. 6, 2021, previously published as PCT/IL2018/050207, filed on Feb. 22, 2018.
Application 17/975,214 is a continuation of application No. 17/334,905, filed on May 31, 2021.
Claims priority of provisional application 62/461,884, filed on Feb. 22, 2017.
Prior Publication US 2023/0065065 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 409/12 (2006.01); A61P 25/28 (2006.01); C07D 487/08 (2006.01)
CPC C07D 409/12 (2013.01) [A61P 25/28 (2018.01); C07D 487/08 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising a compound represented by Formula:

OG Complex Work Unit Chemistry
a tautomer or a pharmaceutically acceptable salt thereof, wherein:
n and m are each integers representing, independently, 1, 2, or 3;
R1 to R4 are substituents, independently in each occurrence selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxy, hydroxy, thiohydroxy, thioalkoxy, aryloxy, thioaryloxy, amino, nitro, halo, trihalomethyl, cyano, amide, carboxy, sulfonyl, sulfoxy, sulfinyl, sulfonamide, substituted or non-substituted; and
R5a-c each represent C1-6 alkyl; and a pharmaceutically acceptable carrier.